Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Jan-Dec:30:963689721999615.
doi: 10.1177/0963689721999615.

Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas

Gu Zhenyang  1 , Li Nainong  2 , Wu Xiaoxiong  3 , Wang Maihong  4 , Fu Xiaorui  5 , Wang Zhao  6 , Ren Hanyun  7 , Li Yuhang  8 , Li Xiaofan  2 , Wu Yamei  3 , Liu Yao  4 , Zhang Mingzhi  5 , Wang Yini  6 , Liu Daihong  1 , Dong Yujun  7 , Hu Liangding  8 , Huang Wenrong  1
Affiliations
Multicenter Study

Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas

Gu Zhenyang et al. Cell Transplant. 2021 Jan-Dec.

Abstract

The number of HLA-haploidentical allogeneic hematopoietic stem-cell transplantation (Haplo-HSCT) is increasing. Comparative studies about Haplo-HSCT versus allo-HSCT with HLA-matched sibling donors (MSD-HSCT) have been tried in leukemias and B-cell lymphomas. Few studies were reported in Peripheral T-cell lymphomas (PTCLs). We performed a multicenter retrospective study about 52 patients with PTCLs undergoing Haplo-HSCT (n = 20) or MSD-HSCT (n = 32). All Haplo-HSCT recipients received antithymocyte globulin (ATG) based graft versus host disease (GVHD) prophylaxis. The median follow-up for all survivors was 38 months. The 100-day cumulative incidence of grade II to IV acute GVHD was similar (19% in the MSD-HSCT group versus 28% in the Haplo-HSCT group, P = 0.52). The 2-year cumulative incidence of chronic GVHD (limited and extensive) after Haplo-HSCT (30%) was also similar with that in the MSD-HSCT group (50%, P = 0.15). The 3-year relapse rates (33% vs 27%, P = 0.84) and non-relapse mortality (21% vs 22%, P = 0.78) did not differ between these two groups. There were also no differences in 3-year overall survival (OS) (48% vs 50%, P = 0.78) and progression-free survival (47% vs 51%, P = 0.95) between these two groups. On multivariate analysis, prognostic index for T-cell lymphoma (PIT) score (higher than 1: hazard ratio [HR], 4.0; P = 0.003) and disease status (stable or progression disease before HSCT: HR, 2.8; P = 0.03) were independent variables associated with worse OS. We concluded that ATG-based haplo-HSCT platform could work as an alternative to MSD-HSCT for patients with PTCLs.

Keywords: HLA-matched sibling donor; allo-HSCT; antithymocyte globulin; haploidentical donor; peripheral t-cell lymphoma.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
(A) Cumulative incidence of 100-day grade Ⅱ-Ⅳ acute graft versus host disease (aGVHD) after allo-HSCT. (B) Cumulative incidence of 2-year limited and extensive chronic GVHD (cGVHD) after allo-HSCT. The cumulative incidences of both aGVHD and cGVHD were estimated with competing-risk analysis and compared with Gray’s test. Haplo-HSCT, allo-HSCT with HLA-haploidentical donors; MSD-HSCT, allo-HSCT with HLA matched sibling donors.
Figure 2.
Figure 2.
(A) The cumulative incidence of non-relapse mortality (NRM) at 3-year was 22% (95% CI, 6%–43%) in the haplo-HSCT group versus 21% (95% CI, 8%–37%) in the MSD-HSCT group. (B) The 3-year relapse rate was 27% (95% CI, 9%–48%) in the Haplo-HCT group versus 33% (95% CI, 17%–50%) in the MSD group. The cumulative incidences of both NRM and relapse were estimated with competing-risk analysis and compared with Gray’s test. Haplo-HSCT, allo-HSCT with HLA-haploidentical donors; MSD-HSCT, allo-HSCT with HLA matched sibling donors.
Figure 3.
Figure 3.
Kaplan-Meier survival analysis. (A) The 3-year overall survival (OS) was 49.9% (95% CI, 31%–80%) in the Haplo-HSCT group versus 48.2% (95% CI, 33%–71%) in the MSD-HSCT group. (B) The 3-year progression free survival (PFS) was 51% (95% CI, 33%–90%) in the Haplo-HSCT groups versus 47% (95% CI, 32%–69%) in the MSD group. Haplo-HSCT, allo-HSCT with HLA-haploidentical donors; MSD-HSCT, allo-HSCT with HLA matched sibling donors.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130. - PubMed
    1. Kwong YL, Anderson BO, Advani R, Kim WS, Levine AM, Lim ST; Asian Oncology Summit. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10(11):1093–1101. - PubMed
    1. Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood. 2013;121(25):4997–5005. - PubMed
    1. Ellin F, Landstrom J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570–1577. - PubMed
    1. Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, Villa D, Gascoyne RD, Connors JM, Savage KJ. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970–1976. - PubMed

Publication types

LinkOut - more resources